▶ 調査レポート

ヒアルロニダーゼの世界市場:成長・動向・市場規模予測(2020-2025)

• 英文タイトル:Hyaluronidase Market - Growth, Trends, and Forecast (2020 - 2025)

Mordor Intelligenceが調査・発行した産業分析レポートです。ヒアルロニダーゼの世界市場:成長・動向・市場規模予測(2020-2025) / Hyaluronidase Market - Growth, Trends, and Forecast (2020 - 2025) / D0-MOR-AP0669資料のイメージです。• レポートコード:D0-MOR-AP0669
• 出版社/出版日:Mordor Intelligence / 2020年4月20日
• レポート形態:英文、PDF、117ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:健康管理
• 販売価格(消費税別)
  Single User¥629,000 (USD4,250)▷ お問い合わせ
  Team User¥703,000 (USD4,750)▷ お問い合わせ
  Corporate License¥1,110,000 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは、ヒアルロニダーゼの世界市場について調査・分析した資料で、ヒアルロニダーゼの市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。

The hyaluronidase market is expected to register a CAGR of 8.5% during the forecast period. Factors such as rising awareness about the change of physical appearance have led to the increasing demand for cosmetics and aesthetics procedures. The demand for hyaluronidase in cosmetic dermatology is increasingly driven by the rise in the prevalence of skin disorders and easy access to advanced cosmetic treatments. Moreover, rising penetration across various application areas and the presence of several clinical studies to determine the efficacy of the products are driving the hyaluronidase market. Moreover, the use of enzyme-based substrate for noninvasive tumor imaging in cancer metastasis, numerous applications in cancer therapy, cosmetic treatments, and ophthalmic therapeutic solutions are also key driving factors in the market. Furthermore, rise in the number of people opting for aesthetic non-surgical procedures, rising geriatric population, and favorable reimbursement policies are also expected to fuel the hyaluronidase market. However, Adverse effects associated with hyaluronidases like skin rashes, unusual weakness may hamper the market.
Key Market Trends

Animal-derived hyaluronidase Segment is Expected to Contribute a Major Market Share in the Hyaluronidase Market

Animal-derived hyaluronidase is contributing to high market share attributing to most of the approved and commercialized brands are derived from animal sources only. Bovine and porcine are some of the widely used animal sources. Hydase (PrimaPharma), Vitrase (Bausch &Lomb Incorporated) and Amphadase(Amphastar Pharmaceuticals, Inc.) are some of the brands manufactured by manufacturers. Moreover, The animal-derived hyaluronidase market has witnessed a substantial number of product approvals leading to promote the growth of the market. For instance, Genentech received FDA approval for Herceptin hylecta which is a subcutaneous injection in which intravenous Herceptin® (trastuzumab) and recombinant human hyaluronidase PH20 enzyme help to deliver trastuzumab to the skin for the treatment of breast cancer patients, hence the market is expected to witness healthy CAGR over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global hyaluronidase market due to the presence of major players manufacturing these products, high adoption of advanced treatment options and a substantial number of dermatology clinics prescribing such treatments. Moreover, increasing healthcare expenditure and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Asia Pacific region is anticipated to witness a lucrative opportunity as a consequence of medical tourism for dermatology treatments and chemotherapy applications. The presence of a substantial number of suppliers with the advent of technology in South Korea is expected to drive the hyaluronidase market. For instance, in 2018, Alteogen developed the world’s second recombinant human hyaluronidase protein and patented protein engineering technology.

Competitive Landscape

The hyaluronidase market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are PrimaPharma, Inc, Amphastar Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Halozyme, Inc., Sun Pharmaceutical Industries Ltd, STEMCELL Technologies, Inc. and CooperSurgical Fertility and Genomic Solutions.

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– 3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Penetration of Hyaluronidase in Correction Procedures
4.2.2 Rising Demand for Minimally Invasive Aesthetic Treatments
4.3 Market Restraints
4.3.1 Adverse Effects associated with Hyaluronidases
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Animal-derived Hyaluronidase
5.1.2 Synthetic Hyaluronidase
5.2 By Application
5.2.1 Chemotherapy
5.2.2 In Vitro Fertilization
5.2.3 Ophthalmology
5.2.4 Dermatology
5.2.5 Others (Plastic surgery)
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 PrimaPharma, Inc
6.1.2 Amphastar Pharmaceuticals, Inc.
6.1.3 Bausch & Lomb Incorporated
6.1.4 Halozyme, Inc.
6.1.5 Sun Pharmaceutical Industries Ltd
6.1.6 STEMCELL Technologies, Inc.
6.1.7 The Cooper Companies, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS